Aliath Bioventures is a company.
Key people at Aliath Bioventures.
Aliath Bioventures was founded by Montserrat Vendrell (Partner and co-Founder).
Aliath Bioventures was founded by Montserrat Vendrell (Partner and co-Founder).
Aliath Bioventures is a Spain-based venture capital firm and healthcare sector impact investment platform within the AltamarCAM group, specializing in life sciences and healthcare investments.[1][2][5] Its mission is to generate competitive financial returns while addressing unmet medical needs and promoting healthcare system sustainability through innovative technologies in biotechnology/biopharma, digital health, medical devices, and diagnostics.[2][5] The firm follows an active investment philosophy, taking board positions in portfolio companies, with a primary focus on European opportunities weighted toward Spain and selective non-European deals; it manages impact-oriented funds like ABV II, AltamarCAM's first Article 9 vehicle under SFDR.[2] Aliath significantly bolsters the European life sciences startup ecosystem by bridging scientific expertise, institutional capital, and operational support, fostering disruptive solutions in high-growth areas like omics, AI-driven data analysis, and neuroprotective therapies.[2][5][6]
Aliath Bioventures emerged from the partnership between AltamarCAM and the Alta Life Sciences team, evolving from Alta Life Sciences SL, which advised AltamarCAM's Alta Life Sciences Spain I FCR fund.[2][5] Launched as an "Alliance for Impact on health," it reflects a strategic fusion to create dedicated life sciences venture capital impact funds under AltamarCAM's umbrella.[2][5] The platform is led by a seasoned team including Montserrat Vendrell, Scott Moonly, and José María Fernández, supported by scientific and VC advisors, with access to AltamarCAM's full platform for legal, ESG, finance, and investor relations.[2] In a recent development, Asabys Partners integrated Aliath Bioventures in late 2025, combining teams with prior co-investments in companies like Deepull, Ona Therapeutics, and Inbrain Neuroelectronics to form a leading European life sciences platform targeting over €1 billion AUM by 2030.[3]
Aliath Bioventures rides the wave of the "omics revolution," AI-enabled data analysis, and accelerating life sciences innovation, timing investments amid unprecedented healthcare discoveries to tackle sustainability challenges.[5] Favorable market forces include Europe's growing life sciences sector, gaps in tech transfer/scale-ups, and demand for impact investing under regulations like SFDR, positioning Aliath to fund disruptive therapies in CNS disorders, diagnostics, and digital health.[2][3][6] By advising AltamarCAM and partnering with Asabys, it influences the ecosystem through capital deployment (e.g., 18+ Asabys investments, 2 exits), board-level support, and collaborations that accelerate therapies like Accure Therapeutics' neuroprotective candidates.[3][6]
Aliath is poised to launch new funds post-Asabys integration, scaling toward €1 billion AUM by 2030 with a focus on high-impact life sciences segments from early-stage to growth.[3] Trends like AI in drug discovery, orphan disease therapies, and sustainable healthcare will propel its portfolio, amplified by its symbiotic model of investor-entrepreneur alliances.[2][5] Its influence will likely expand as a pan-European powerhouse, driving more exits and innovations that redefine accessible medicine—echoing its core mission to alliance-build for global health impact.[2][5]
Key people at Aliath Bioventures.
